Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anemarrhena rhizome is the dried rhizome of *Anemarrhena asphodeloides* Bunge, a plant widely used in traditional Chinese medicine (TCM) where it is known as Zhi Mu. It contains bioactive compounds such as steroidal saponins (notably timosaponin A-III) and xanthones (like mangiferin). Research indicates that Anemarrhena rhizome exhibits anti-diabetic, anti-inflammatory, and anti-tumor properties. In the context of oncology, it has been shown to inhibit cell viability and induce apoptosis in pancreatic cancer cell lines by increasing caspase 3/7 activity. Historically, it is used to treat conditions associated with internal heat and yin deficiency, including febrile diseases and diabetes mellitus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anemarrhena rhizome.